New startup bets $1.2 billion on genetically modified military canines

A new billion dollar venture has emerged to solve a critical logistical gap in U.S. defense by engineering dogs with superior physical traits.

Warhound launched on Thursday with a $200 million funding round that values the company at $1.2 billion. The capital comes from a group of investors that includes Sequoia, 8VC, and Corner Ventures. The lineup also features In-Q-Tel, a venture firm backed by the CIA and other U.S. intelligence agencies. This financial backing signals a serious commercial push to modernize a sector that has relied on traditional breeding methods for decades.

The core business case rests on a declining domestic supply of qualified working dogs. According to the company, more than 80% of the U.S. military’s working dogs are imported from Europe. Furthermore, less than half of those imported animals are fit for service upon arrival. This dependency creates a strategic vulnerability for defense and law enforcement agencies that rely on these animals for bomb detection and search operations. Warhound seeks to disrupt this market by creating a new type of dog engineered for longevity, health, and specific performance metrics.

The technology behind the venture is a collaboration between Colossal Biosciences and Anduril. Ben Lamm of Colossal and Palmer Luckey of Anduril developed the concept after meeting a year ago. Lamm noted that many traditional working dogs fail training due to inherited issues like poor eyesight or hip dysplasia. The team plans to use cell lines from top-performing breeds such as Belgian Malinois and German Shepherds. They will edit the genes to remove negative traits and enhance speed, agility, and olfactory senses. Anduril will provide the hardware and software, including protection vests and goggles with data sensors, to improve situational awareness for both the dogs and their handlers.

The operational timeline is aggressive. The first batch of dogs is expected to be cloned and incubated soon, with births anticipated early next year. The company aims to have the animals in service within two years. Viagen, another entity owned by Colossal, will handle the cloning process using its existing technology. While the exact pricing model is not yet public, the target customers include the Department of Defense, police forces, and first responders.

Leadership at Warhound emphasizes that the genetic enhancements are the foundation, while Anduril’s gear provides the technological layer. Lamm explained that the goal is to keep the dogs safer and more effective in the line of duty. Luckey serves as a partner in the venture but holds no equity. Colossal owns equity and licenses its technology to the new company. This structure separates the biological innovation from the tactical equipment, creating a distinct value proposition in the defense tech market.

The company is working with the American Humane Society to certify its training program. The society’s involvement addresses potential public concerns about the welfare of genetically modified animals in service. The group stated it looks forward to ensuring the animals are treated humanely. Warhound also plans to integrate retired dogs into reunification programs, providing a clear end-of-life pathway for the workforce.